Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Wow up 25% lol .
ALTU just hit .40 nice move!
ALTU keep on radar Bio plays hot. According to yahoo .80 c a share cash and no debt.
ALTU Bio Play 26m float 25m cash NO DEBT.
VTRO .19 could start up
ZHNE nice volume
ZHNE nice day so far
ALTI looking like it wants to go.Alt energy
LBIX getting some volume.
CHART http://stockcharts.com/h-sc/ui?s=LBIX&p=DAILY&b=5&g=0&id=p41832985753
LBIX moving up NASDAQ small float
LBIX 17 m Float at .20
SCLD HRSH all up LBIX maybe next
MDLK huge day radar LBIX,SCLD,HRSH,HSWI for tomorrow
MDLK now .30's keep an eye on LBIX
LBIX starting to move up.
LBIX keep on radar for volume.
MDLK now .19
MDLK now .16
MDLK looking good here
MDLK volume spike could crush a big short here.
RODM now .89
NLST moving up
RODM now .57 from .40 entry
EFJI play on Obama internet security they are Homeland Dept. Security
It also offers secure wireless networking solutions that include Wi-Fi products, mesh networking, access points, bridges, and client infrastructure products, as well as security software and custom solutions; and encryption technologies for wireless voice, video, and data communications
Its customers include public safety/public service entities; federal, state, and local governmental agencies, including the Departments of Homeland Security and Defense
TELK at HOD next ASCO runner
TELK broke .70's could run tomorrow.
TELK looks like it wants to run soon 51m float
presenting at ASCO
RODM no debt low float up from post at .40 more recent transactions
with VICL and Rexahn pharmacueticals.
CYCC back over .90
RODM low float recent large transactions with HEB GNTA FEED
.58 cents/share cash
http://stockcharts.com/h-sc/ui?s=RODM&p=DAILY&b=5&g=0&id=p27284206341
Shykora's Sell button jammed up.
RODM low float starting to move up
Co has no debt.
May transactions alone with HEB GNTA FEED
website
http://www.rodmanandrenshaw.com/
Chart
http://stockcharts.com/h-sc/ui?s=RODM&p=D&b=5&g=0&id=p09172376097
RODM Low Float NO DEBT at.40 (cash per share .58) did placement for HEB
Rodman & Renshaw Capital Group, Inc., through its subsidiaries, provides investment banking services to public and private biotechnology companies.
http://stockcharts.com/h-sc/ui?s=RODM&p=DAILY&b=5&g=0&id=p85122239757
RODM Low Float NO DEBT .40 cash per share .58
Rodman & Renshaw Capital Group, Inc., through its subsidiaries, provides investment banking services to public and private biotechnology companies.
http://stockcharts.com/h-sc/ui?s=RODM&p=DAILY&b=5&g=0&id=p85122239757
RODM at .39
low float .58c cash/share
Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
chart
http://stockcharts.com/h-sc/ui?s=RODM&p=DAILY&b=5&g=0&id=p75469086919
RODM low float at .39 .58c cash
Rodman has been a leading investment banking firm to the biotechnology sector, a capital intensive market segment, as well as a leader in the PIPE (private investment in public equity) and RD (registered direct placements) transaction markets.
CYCC at ASCO
Poster presentation and oral poster discussion details are as follows:
Sapacitabine
"A randomized phase II study of sapacitabine, an oral nucleoside
analogue, in elderly patients with AML previously untreated or in
first relapse or previously treated MDS"
Date/Time: Friday May 29, 2009, 2:00 P.M. - 6:00 P.M. Eastern Time
Abstract Number: 7021
Location: Level 2, West Hall, Board 13
Discussion time: 5:00 P.M. - 6:00 p.m. Eastern Time
Location: Level 2, West Hall F1
Seliciclib
"A phase II randomized study of oral seliciclib in patients with
previously treated nasopharyngeal carcinoma"
Date/Time: Friday May 29, 2009, 2:00 P.M. - 6:00 p.m. Eastern Time
Abstract Number: 6026
Location: Level 2, West Hall, Board 15
Discussion time: 5:00 PM - 6:00 P.M. Eastern Time
Location: Level 2, West Hall F3
RODM 34m float no Debt! at .39 58c cash/share
may pick up some here.
CYCC from May 15 3$ price target
Cyclacel likely to report positive sapacitabine data at ASCO, says Piper Jaffray
Piper Jaffray said they expect CYCC to report positive interim data for sapacitabine at ASCO in May. The firm notes that dose selection for the pivotal trial in elderly acute myelooid leukemia and myelodysplastic syndrome will be revealed and notes complete responses have been seen at all 3 does investigated. Shares are Buy rated; target $3. :